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the acceptance and commissioning of medical radiological equipment, 
need to be fulfilled by or under the oversightof or with the 
documented advice of a medical physicist. The degree of involvement 
of the medical physicist in diagnostic uses and image-guided 
interventional procedures is determined by the complexity of the 
radiological procedures and the associated radiation risks.  
In conclusion, the new BSS identifies the medical physicist as a key 
professional with a specialized training, skills and competence in 
clinical medical physics and radiation protection. The medical 
physicist has significant responsibilities in the many activities that are 
needed to successfully implement the quality assurance programme 
and radiation protection principle of optimization for medical 
exposure in a given hospital or medical centre. If these new BSS 
requirements are effectively implemented, they will help pave the 
way for a full recognition of the medical physicist as a health care 
professional alongside other professionals working in the medical 
field. 
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Purpose/Objective:  Imaging for patient positioning is part of the 
image guided radiation therapy (IGRT) workflow and is routinely used 
in clinical practice. The primary objective is to check and correct the 
patient position with such an improved day to day reproducibility that 
dose delivery to the target volume and organs at risks is the most 
similar to the planned one. This can be accomplished by plenty of 
imaging techniques based on kV, MV or ultrasound imaging and made 
available by companies in various mechanical configurations. The 
objective of this teaching lecture is to provide an overview of the 
different techniques used and to evaluate their respective pros and 
cons. 
Materials/Methods: A review of literature is presented from the 
simplest two dimensional imaging techniques to the most advanced 
ones capable of imaging the movement of the patient in four 
dimensions (4D). Special focus is presented on high precision 
irradiation techniques such as stereotactic radiosurgery, where 
treatment outcome is the most dependent on accurate patient 
positioning.  
Results: Globally, the performance of the most advanced imaging 
techniques allows us to position the patient and the target volume 
within millimeters and even under 1 mm for parts of the body which 
can be rigidly immobilized. Also taking into account target volume 
movements with 4D imaging techniques prior to treatment, e.g. for 
lung treatments, allow us to reduce the irradiated volume and 
therefore potentially reduce toxicity. The great improvement of 
imaging techniques in recent years raises then the question of the 
interest of frameless high precision irradiation techniques, because 
these techniques, based on imaging without invasive frame 
contention, are definitely providing equivalent degree of accuracy in 
patient positioning.  
Conclusions: IGRT techniques for patient positioning are widespread 
in clinical practice. Recent improvements allow us to position the 
patient and the target volume within 1mm accuracy. Most advanced 
techniques even take into account target movement by 4D imaging of 
patient positioning. Stereotactic high precision irradiation based on 
frameless imaging also challenges the usual invasive frame-based 
technique for patient positioning precision. 
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The strength of brachytherapy (BT) is that the radiation sources are 
inside or in the vicinity of the target volume and that they generally 
move with the target. The target dose is high and due to the inverse 
square law the dose to the surrounding normal tissue (organs at risk) 
can be reduced considerably. Therefore, BT has gained a definite 
place in the treatment of patients with gynaecological, head and 
neck, breast and prostate tumours.  
Brachytherapy has been applied since 1901, a few years after the 
discovery of x-rays and radium. Important developments in the 
medical application of radionuclides were the dosimetry systems 
(Stockholm, Paris, Manchester), the discovery of artificial 
radioactivity ( 60Co,137Cs, 198Au, 192Ir) and the development of 
remote afterloading devices. 
The field of BT continues to develop and the introduction of new 
technology brings new questions and challenges [1]: 
new afterloading devices, new dose calculation algorithms, 3D image 
based dose planning, new applicators,  application of knowledge of 
radiobiology to optimize treatment schedules, robotic brachytherapy 
for prostate seed implant, electronic brachytherapy sources and in 
vivo dosimetry. 
 A major improvement of BT may be expected from the use of 3D 
imaging, especially magnetic resonance imaging (MRI).  MRI does not 
completely replace clinical investigation and other imaging 
modalities, but its superior soft tissue contrast often helps to better 
define tumor stage, target volume extension and organs at risk at 
time of diagnosis, at time of BT and for treatmentplanning purposes.  
During the last years we see a development towards MR guided BT in 
different tumor sites(gynaecology, prostate). This presentation will 
focus on technology for MRI guided BT and how anatomical and 
functional MRI optimize and individualize BT approaches. 
1. Venselaar JL, Baltas D, Meigooni AS, Hoskin PJ (editors), 
Comprehensive Brachytherapy; Physical and Clinical Aspects, CRC 
Press, 2012. 
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Superficial esophageal cancer (SEC) is defined as esophageal cancer 
limited to the submucosal layer and includes mucosal and submucosal 
cancer. Based on the criteria of the Japanese Society for Esophageal 
Disease, Mucosal and submucosal cancer is classified according to 
location: epithelial layer (m1); proper mucosal layer (m2); muscularis 
mucosa (m3); upper third of the submucosal level (sm1); middle third 
of the submucosal layer (sm2); and the lower third of the submucosal 
level (sm3). Irrespective of the treatment method, the depth of 
invasion is one of the most important prognostic factors of SEC 
because lymph node metastasis markedly increases in lesions 
infiltrating the lamina muscularis mucosa (m3).  
The best management of small m1 and m2 esophageal cancer is 
generally endoscopic resection (ER). For m3-sm3 SEC, extensive lymph 
node dissection has been the most popular choice of 
treatment.However, after introduction of chemoradiation therapy, 
good treatment outcomes which are comparable with those of surgery 
have been reported. In a Japanese phase II study of CRT for T1 
esophageal carcinoma (JCOG 9704), 4 and 5 year overall survival rates 
were 80.5% and 76.5%, respectively. In our prospective single 
institutional phase II study, local control rate, and overall survival 
rate was 80.3%, % 78.9and % respectively. From these data, we think 
CRT for early state esophageal carcinoma is one of the standard 
treatment methods.  
Combination of ER and CRT is another approach. If the depth of 
invasion reached to submucosa, surgery has been added to most 
patients because of the high rate of lymph node metastasis. However, 
treatment outcomes of post ER CRT to prevent lymph node recurrence 
seems to be excellent and this approach may become a standard 
treatment method for endoscopically resectable esophageal cancer.  
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Early-stage esophageal cancer can be defined as locally resectable 
disease ((1) Ever since, several important developments (including 
Barrett surveillance, improvement of clinical staging by e.g. PET 
scanning, centralization of care, refined perioperative therapy, and 
more radical surgical techniques) have improved short-term and long-
term outcome. However, 5-year survival after potentially curative 
surgical resection still rarely exceeds 35%. 
Many clinical trials have tested the potential value of neoadjuvant 
chemo- and/or radiotherapy to improve long-term outcome. In five 
randomized controlled trials (RCTs) the efficacy of neoadjuvant 
radiotherapy has been tested. A meta-analysis showed a non-
significant 4% increase of 5 year survival rate.(2) Nine RCTs have been 
